IR-Med, Inc. Announces the Appointment of Dr. Rom Eliaz as Chief Executive Officer
New York, NY, June 25, 2021 (GLOBE NEWSWIRE) -- IR-Med, Inc. (OTCPINK: IRME) announced today the appointment of Dr. Rom Eliaz as Chief Executive Officer.
Prior to his appointment as our CEO, Dr. Eliaz was Founder and Managing Director at Elrom Ventures, where he also served as a Managing Director at aMoon Fund. Previously, Dr. Eliaz was Head of Merck ventures’ Fund and Bio-Incubator in Israel where he co-founded several companies in the incubator, VP of Innovative Branded Products at Teva and CEO of NasVax a publicly traded company and Immcure Therapeutics.
“We are pleased to have a seasoned life sciences and medical devices executive like Rom joining us as our CEO. His scientific and financial experience will be instrumental as we continue implementing our strategy to develop sensor based medical devices, developing point of care solutions for early identification and monitoring of chronic, preventable conditions” explained Oded Bashan, Chairman of the Board at IR-Med.
Commenting on his appointment as CEO, Rom Eliaz added, “I am incredibly excited and honored to be joining IR-Med. I believe IR-Med is one of the companies that are working to modernize care pathways through developing and integrating new-to-the-world sensor-based medical devices in truly unmet medical needs, and to actively contribute to becoming the leader in these fields. I am privileged to lead our mission-driven company into the next wave of growth. We have a tremendous opportunity here at IR-Med to leverage emerging technologies and data-driven insights to transform and sustainably mange patients healthcare for the long-term.”
Dr. Eliaz served as Assistant Professor at University of California San Francisco, published over 40 scientific articles and holds more than 10 scientific patents in the fields of drug targeting and delivery, gene therapy and tissue engineering.
Dr. Eliaz received his PhD (cum-laude) in chemical engineering and Biotechnology from the Weizmann Institute and Ben-Gurion (BGU). His BSc and MSc degrees, with honors, in chemical engineering and Biotechnology are from BGU, and he holds an MBA from the Harvard Business School and Boston University joint program at BGU.
About IR-Med Ltd.
IR-Med Ltd is a development stage company currently focused on the development and application of Infra-Red (IR) and Artificial Intelligence (AI) technologies to address common medical ailments. Initially IR-Med’s technologies are designed to address the early detection of pressure injuries (PI) and the detection and diagnosis of ear infection, primarily in children. For more information visit http://www.ir-medical.com.
Forward Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods; our business and product development plans; or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business plan and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. The Company does not undertake any obligation to publicly update any forward looking statement. Neither the Company nor I.R MED are subject to the reporting requirements of the Securities and Exchange Commission under the Securities and Exchange Act of 1934 as amended.
Upcoming Life Sciences Events
- February 2022
- Biotechgate Digital Partnering February 2022
- BIO CEO & Investor Conference
- March 2022
- Zurich: Swiss Nordic Bio 2022